HOLX:NSD-Hologic Inc (USD)

COMMON STOCK | Medical Instruments & Supplies |

Last Closing

USD 72.68

Change

+0.18 (+0.25)%

Market Cap

USD 17.14B

Volume

0.88M

Analyst Target

USD 77.73
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Hologic, Inc. engages in the development, manufacture, and supply of diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment worldwide. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth. The company also offers breast cancer care solutions in the areas of radiology, breast surgery, pathology, and treatment, such as 3D digital mammography systems, image analytics software, reading workstations, minimally invasive breast biopsy guidance systems, breast biopsy site markers, localization, and specimen radiology solutions; and breast conserving surgery products. In addition, it provides MyoSure Hysteroscopic Tissue Removal System for the removal of fibroids and polyps in the uterus; NovaSure Endometrial Ablation System to treat abnormal uterine bleeding; Fluent Fluid Management System that provides liquid distention during diagnostic and operative hysteroscopic procedures; Acessa ProVu system to treat various fibroids; and CoolSeal portfolio, such as bipolar vessel sealing devices. Further, it offers Horizon DXA, a dual energy X-ray system; and Fluoroscan Insight FD mini C-arm to perform minimally invasive orthopedic surgical procedures. It sells its products through direct sales, service forces, independent distributors, and sales representatives. The company was incorporated in 1985 and is headquartered in Marlborough, Massachusetts.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-12-24 )

Largest Industry Peers for Medical Instruments & Supplies

Symbol Name Price(Change) Market Cap
ISRG Intuitive Surgical Inc

+9.80 (+1.86%)

USD 192.19B
COO The Cooper Companies, Inc. Com..

+0.29 (+0.31%)

USD 18.65B
ALGN Align Technology Inc

+5.93 (+2.86%)

USD 17.86B
RGEN Repligen Corporation

+1.30 (+0.89%)

USD 8.36B
MMSI Merit Medical Systems Inc

+0.47 (+0.48%)

USD 6.15B
ICUI ICU Medical Inc

+2.19 (+1.42%)

USD 3.97B
XRAY Dentsply Sirona Inc

-0.05 (-0.26%)

USD 3.92B
LMAT LeMaitre Vascular Inc

+1.25 (+1.37%)

USD 2.27B
AZTA Azenta Inc

+0.22 (+0.44%)

USD 2.08B
ATRC AtriCure Inc

-0.01 (-0.03%)

USD 1.67B

ETFs Containing HOLX

TUHY:CA TD Active U.S. High Yield.. 2.14 % 0.00 %

-0.07 (0.75%)

CAD 0.14B
FDWM Fidelity Covington Trust .. 1.85 % 0.00 %

+0.17 (+0.75%)

USD 4.77M

Market Performance

  Market Performance vs. Industry/Classification (Medical Instruments & Supplies) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 1.72% 64% D 53% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 1.72% 64% D 49% F
Trailing 12 Months  
Capital Gain 2.21% 64% D 54% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 2.21% 64% D 50% F
Trailing 5 Years  
Capital Gain 38.86% 74% C 71% C-
Dividend Return N/A N/A N/A N/A N/A
Total Return 38.86% 74% C 67% D+
Average Annual (5 Year Horizon)  
Capital Gain 7.03% 51% F 56% F
Dividend Return 7.03% 51% F 53% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 26.35% 84% B 68% D+
Risk Adjusted Return 26.68% 74% C 59% D-
Market Capitalization 17.14B 92% A 95% A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

What to not like:
Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector